Dr Reddys Laboratories Ltd

- Capex cash outflow for Q3FY26 was ₹669 crores (US$75 million). - Focus on strategic investments and value-accretive acquisitions and partnerships to create long-term value. - Ongoing investments in differentiated R&D programs, especially peptides and biosimilars, targeting meaningful commercial opportunities. - Emphasis on expanding innovation portfolio for India and Emerging markets via in-house development and strategic collaborations. - Aurigene CDMO opportunity: growing emphasis on exclusive supply of innovative APIs, expected to yield over $100 million revenue growth in next 2-3 years. - Continued investment in branded businesses across India, Emerging markets, and NRT. - Capex and investments aim to support pipeline products like Semaglutide and Abatacept, and enhance operational efficiencies.

- Europe sales expected to grow up to 10 times the 2018 level in the next 2-3 years, driven by biosimilars and Abatacept launch; double-digit growth anticipated in all European markets excluding the US. - India business growth sustainable at 15-16%, possibly higher than 19%, supported by innovative products, new acquisitions, and Semaglutide launch. - Emerging markets like Russia to deliver healthy double-digit sustainable growth through a mix of new and existing products. - Global generics gross margins expected between 50-55% post-Lenalidomide impact. - Aurigene CDMO business anticipated to contribute $100+ million in revenue growth in 2-3 years. - Semaglutide approval and launch in key markets like Canada planned between Q4 FY26 to Q1 FY27, with competitive pricing expected near the lower end of $20-$70 per unit. - Ongoing investments in R&D, pipeline products, and strategic partnerships to drive long-term growth.

- Revenue growth expected to be supported by double-digit growth in all markets except the U.S. (single-digit growth). - European sales expected to potentially increase 10 times from EUR 100 million in 2018 over the next 2-3 years, emphasizing Europe's strategic importance. - EBITDA margin around 25%, with some quarters performing above this, reflecting strong profitability. - SG&A spend to grow at a moderated rate, controlled to be less than half the growth rate of top-line revenue, indicating cost discipline. - Gross margin for Global Generics and PSAI projected between 50-55% post Lenalidomide sales end. - Profit after tax fell 14% YoY in Q3FY26, but company is managing cost and growth for steady improvement. - EPS in Q3FY26 was ₹14.52; future growth implied but not explicitly quantified. - Overall, sustainable double-digit growth expected from emerging markets and innovation-driven segments.

The transcript from the Q3FY26 Earnings Call does not specifically mention details about the company's current or expected order book or pending orders. Key points related to business outlook and growth include: - Strong growth in biosimilars and generics across regions including Europe, India, North America, and emerging markets. - Launch of Abatacept in Europe expected by July 2027. - Continued investment and growth in branded business and CDMO with Aurigene Pharmaceutical Services. - Focus on advancing pipeline products like Semaglutide, Abatacept. - Expected double-digit growth in most markets excluding single-digit growth in the United States. - No specific commentary provided on order book or pending orders. Hence, no explicit data on order book or pending orders is available in the transcript.

The transcript on page 19 and surrounding pages does not mention any current or future plans for fundraising through debt or equity. Key points related to finances include: - The company ended the quarter with a net cash surplus of US$342 million (Page 6). - Capex cash outflow was US$75 million for the quarter (Page 5). - There is no disclosure or indication of plans for raising funds through debt or equity in the near future. - The company expressed focus on cost containment and controlling SG&A expenses (Page 17), implying a conservative financial approach. - No questions or answers in the transcript addressed fundraising activities. Therefore, based on the Q3FY26 earnings call, there are no announced plans for raising capital via debt or equity.